Scorpion Therapeutics forges AstraZeneca deal worth up to $1.6B

Cancer-focused precision medicine startup Scorpion Therapeutics, founded by serial entrepreneur Gary Glick and now headed up by GlaxoSmithKline plc veteran Axel Hoos, has made its next major move: signing a collaboration agreement worth up to $1.6 billion with the pharmaceutical giant AstraZeneca plc.